Przemyslaw Twardowski MD
Genitourinary Oncology, Hematologic Oncology
Professor of Medical Oncology and Urologic Oncology , Director of Clinical Research, John Wayne Cancer Institute, Santa Monica , CA
Join to view full profile
2121 Santa Monica BlvdSanta Monica, CA 90404
Phone+1 310-582-7137
Fax+1 310-582-7140
Dr. Twardowski is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1994 - 1997- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1993 - 1994
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1990 - 1993
University of Missouri-Columbia School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1998 - 2028
IL State Medical License 1990 - 1999
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts FollowMyHealth, Allscripts, 2013-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2013-2017
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
Clinical Trials
- SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Publications & Presentations
PubMed
- Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.Anishka A D'Souza, Susan G Groshen, Denice Tsao-Wei, Nora Ruel, Tanya B Dorff
Current Problems in Cancer. 2026-08-01 - Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel.Stephen J Freedland, William Aronson, Arash Asher, Mitch Golant, Emily Lemke
Journal of the National Comprehensive Cancer Network. 2026-03-31 - CD8 PET imaging with [Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.Michael A Postow, Peter D Zang, Sumanta K Pal, Audrey Mauguen, Michael Farwell
Journal for Immunotherapy of Cancer. 2026-03-27
Journal Articles
- Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerMaha Hussain, Neeraj Agarwal, Przemyslaw Twardowski, The New England Journal of Medicine
Press Mentions
Advanced Prostate Cancer: Experts Say This Double Therapy Can HelpMarch 30th, 2023- Prostate Cancer ADT Has Fewer Cardiovascular Risks Than ExpectedJanuary 12th, 2022
- 25 Warning Signs Your Kidneys Send YouJune 8th, 2020
Grant Support
- (PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational researchBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2019–2025
- (PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational researchBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2019–2025
- Biologic Markers Of Angiogenesis: A Companion Study To "Phase I Trial Of OralNational Center For Research Resources2005
- Phase I Trial Of Oral Cyclophosphamide With CelecoxibNational Center For Research Resources2004
- Phase I Trial Of Etoposide In Combination W/ CelecoxibNational Center For Research Resources2004
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
